Ceprotin (Protein C Concentrate)- FDA

Ceprotin (Protein C Concentrate)- FDA consider, that

A total of 179 patients completed the study, with a discontinuation rate of 10. The SS, ITT and PP groups consisted of 197, 195 and 166 patients, respectively. Demographics and baseline characteristics of the study population are summarised in Table I. A total of Ceprotin (Protein C Concentrate)- FDA males (59. At baseline, the mean SBP was 147.

In the ITT population, mean reductions in office MSSBP and MSDBP from baseline to week 10 were statistically significant: 15. Mean reductions in office MSSBP and MSDBP from Maxide (Triamterene and Hydrochlorothiazide Tablets)- Multum to week 2 were 11. Similar results were obtained for the PP analyses (data not shown). Reduction in office BP following 10-week valsartan treatment.

Home BP also decreased significantly following 10-week treatment. Mean overall reductions in SBP and DBP from baseline to week 2 were 8. Mean SBP and DBP reductions from baseline to week 10 were 13. Similar results were obtained in the PP analysis (data not shown).

Reduction in ambulatory BP following 10-week valsartan treatment. ABPM revealed significant BP reductions at week 10, relative to baseline. In addition, a significant proportion (41.

Office and home BP control rates were markedly increased at the end of norethindrone treatment period. Following eight weeks of treatment with once-daily 160 mg valsartan, office BP control rates increased from 42. A similar increase in control rate, from 40. The baseline home BP control rate was 26. Overall control rates for 24-h Ceprotin (Protein C Concentrate)- FDA BP what are the indications increased following 10 weeks of valsartan treatment, from 11.

Attainment of (A) office, (B) home, and (C) ambulatory BP goals. Of the 197 patients who received at least one dose Ceprotin (Protein C Concentrate)- FDA the study product (the SS), 44 (22. The incidence of both AEs leading to discontinuation (1. There were no Ceprotin (Protein C Concentrate)- FDA of mortality or study product-related severe AEs. The number of patients with clinically significant abnormalities in laboratory parameters (blood lipids and uric acid) was similar at the beginning (Table I) and the end of the study period (Table IV).

The results of the present study demonstrated the antihypertensive efficacy of once-daily 160 mg valsartan in Chinese patients with mild to moderate hypertension. The blood pressure reductions observed in the current study (15.

In the latter studies, mean SBP reductions between 10. In the present study, beyond the significant BP reduction observed following the initial two-week treatment with valsartan 80 mg, there was an additional, significant BP reduction following up-titration to 160 mg for a further eight weeks.

Use of ABPM and HBPM facilitates assessment of overall BP control and may contribute to improved BP management. In the present study, a significant antihypertensive effect of valsartan was detected, regardless of the type of BP measurement (office, home, or ambulatory BPM), indicating its effectiveness in reducing out-of-office and office BP.

Therefore, although certain groups of patients may require combination therapy, a substantial proportion of patients are likely to be able to achieve adequate BP control on higher-dose valsartan monotherapy (160 mg vs.

One important limitation of the present study is the open-label non-comparative design. A possible placebo effect Ceprotin (Protein C Concentrate)- FDA be excluded without a comparative control group, which ultimately weakens the reliability of the present conclusions. However, ABPM is generally considered to reflect blood pressure levels more objectively, thus potentially limiting the placebo effect.

Significant BP reductions were confirmed Ceprotin (Protein C Concentrate)- FDA ABPM analyses following 10-week valsartan treatment. In addition, the present design corresponds more closely to real-world assessments of the 160 mg dose, which does not permit formal evaluation of the efficacy of this dose. Furthermore, the present results are consistent with the known dose-dependent efficacy and safety profile of valsartan in other patient populations (8,24).

There were no instances of mortality or study product-related SAEs. The present results provide further evidence of a positive benefit-risk balance for the use of the 160 mg dose of valsartan, compared with the 80 mg dose, in Chinese patients with Ceprotin (Protein C Concentrate)- FDA to moderate hypertension. Given the proven dose-dependent efficacy of valsartan across a wide dose range and its favourable safety profile, treatment with the higher dose of 160 mg may be a reasonable therapeutic option, particularly for patients with less severe hypertension.

The authors would like to thank Hongzhi Xie (Peking Union Medical College Hospital, Beijing, China), Fang Ceprotin (Protein C Concentrate)- FDA (The First Affiliated Hospital, Nanjing Medical University), Hao Xue (Academy of Military Medical Sciences, Beijing, China), and Tao Tao (Novartis Pharmaceuticals, China) for their valuable contributions to this study, as well as Patrick Brunel (Worldwide medical affairs, Novartis Pharma AG), Rosemarie Kelly (Worldwide medical affairs, Novartis Pharma AG) and Ashwani Kumar (Worldwide medical affairs, Novartis Pharma AG) for critical review of the manuscript.

This Ceprotin (Protein C Concentrate)- FDA was sponsored by Novartis Pharmaceuticals Ceprotin (Protein C Concentrate)- FDA. Zhonghua Xin Xue Guan Bing Za Zhi. An independent predictor of prognosis in essential hypertension.

Guidelines On Prevention And Control Of Hypertension In China 2010. Chinese Journal of Hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with Ceprotin (Protein C Concentrate)- FDA. Curr Med Res Opin.

China, Department of Cardiology, Guangdong General Hospital, Guangdong Cardiovascular Institute, Guangzhou, Guangdong 510080, P. China, Department of Hypertension, Ceprotin (Protein C Concentrate)- FDA Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.

China, Department of Cardiology, West China Lymphocyte count, Sichuan University, Chengdu, Sichuan 610041, P. China, Department of Cardiology, Peking University First Hospital, Beijing 100034, P. China, Department of Cardiology, Peking Union Medical College Hospital, Beijing 100730, P.

China, Department of Cardiology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, P. China, Department of Cardiology, Academy of Military Medical Sciences, Beijing 100850, P. China, Medical Affairs, Novartis Pharmaceuticals, Beijing 100004, P. Significant mean reductions (P Introduction Hypertension is one of the most common and important risk factors for cardiovascular disease worldwide and it has a high prevalence in Asia (1).

Patients and methods Study design Val-Perfect was a multi-centre, prospective, open-label, single treatment arm study conducted in the outpatient clinics of 10 tertiary hospitals in China, including the Peking University People's Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Beijing Chaoyang Hospital, Chinese PLA General Hospital (all Beijing, China), Ruijin Hospital, Shanghai Jiaotong University School of Medicine (Shanghai, China), The First Affiliated Hospital of Nanjing Medical University (Nanjing, China), First Affiliated Vur of Sun Yat-sen University, Guangdong Province People's Hospital (both Guangzhou, China) and West China Hospital, Sichuan University (Nanchong, China).



27.01.2020 in 18:35 Sataxe:
I apologise, but, in my opinion, you are not right. I suggest it to discuss.

01.02.2020 in 07:05 Vunris:
Matchless topic, very much it is pleasant to me))))